中文

← All funding rounds

Isomorphic Labs

EuropeDrug discoveryLondon, United KingdomFounded 2021Private

Website · isomorphiclabs.com ↗Company profile on this site →

Alphabet's drug-design company, spun out of DeepMind to build on AlphaFold: it builds AI models to design drug candidates for its own pipeline and for pharma partners.

Disclosed total$2.7B
Rounds on record31 in talks
Latest round$2.1BSeries B · 2026-05-12
Last stated valuation$40Bstated by Bloomberg
Investors named7
Research on record2highest level 3 · Checked against existing evidence

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date20252026$600M$2.1BRound (unnamed) (talks)Evidencelevel of each research entry12345
Closed roundIn talksNot on the dollar scale (a range, or no rate)Research entry, at its level

Latest round, Round (unnamed) (in talks), 2026-10-08: the record then held 2 research entries, highest level 3. The first research entry is dated 2024-05-08; the highest level so far is 3 (Checked against existing evidence).

Rounds and research, on one timeline

  1. 2026-10-08Round (unnamed)In talks
    Round

    Amount not reported$40B · stated by Bloomberg

    Not stated

    Early talks, per people familiar: at least $40B, possibly as high as $50B; not closed, and Isomorphic did not comment.

    No investor named in the source.

    Reported by Bloomberg via Yahoo Finance · finance.yahoo.com ↗On the timeline →

  2. 2026-05-12Series B
    Round

    $2.1B

    For: developing and deploying its drug design engine (IsoDDE), moving programmes toward the clinic, and hiring

    Models and platformToward the clinicHiring

    Isomorphic remains an Alphabet company; the release gives no valuation.

    Lead · Thrive CapitalAlphabetGV ✓MGX ✓TemasekCapitalG ✓UK Sovereign AI Fund ✓

    On the deal: Joséphine Kant (Head of Ventures, UK Sovereign AI Fund); Joshua Kushner (Founder and CEO, Thrive Capital); Krishna Yeshwant (Managing Partner, GV); Ruth Porat (President and Chief Investment Officer, Alphabet and Google, Alphabet)

    By this date the record held 2 research entries, highest level 3

    Announced by the company · isomorphiclabs.com ↗On the timeline →

  3. 2026-02-10
    Research

    Level 2 · Computed

    Isomorphic Labs' technical report says its drug design engine IsoDDE doubles AlphaFold 3 on the hardest unseen protein-ligand cases, scored by Isomorphic itself and with the method undisclosed

    AlphaFold-style models mostly fail on pockets and antibodies unlike what they were trained on, and that is where new drugs are. This report says Isomorphic has closed much of that gap, and the engine is part of what its $2.1B Series B pays for. But every number is computed and scored by Isomorphic itself, the method is withheld, and no outside team can check it. No molecule designed with it has public results.

    Timeline entry →doi.org ↗

  4. 2025-03-31Round (unnamed)
    Round

    $600M

    For: its AI drug design engine and moving its own programmes into clinical development

    Models and platformToward the clinic

    The release calls it the company's first external funding round and gives no series letter; the May 2026 round is named Series B.

    Lead · Thrive CapitalGV ✓Alphabet (follow-on)

    On the deal: Joshua Kushner (Founder and CEO, Thrive Capital); Krishna Yeshwant (Managing Partner, GV)

    By this date the record held 1 research entry, highest level 3

    Announced by the company · prnewswire.com ↗On the timeline →

  5. 2024-05-08
    Research

    Level 3 · Checked against existing evidence

    AlphaFold 3 predicts interactions across biomolecules

    Structure prediction moves closer to the interaction problems central to drug discovery, while restricted access triggers an openness dispute.

    Timeline entry →nature.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

On the investors' own sites

Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.

Its investors also backed

Other companies on this page whose rounds name the same investor.